We also determined whether CXB, as an adjuvant agent, could reduce the dosage of TAM and its consequences in potentially reducing VEGF- and VEGFR2-mediated insensitivity in breast cancer cells to TAM. The gene discussed is VEGFA; the disease is breast carcinoma.